Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel - Results From the COU-AA-301 Phase 3 Study

被引：1
|
作者：
Sternberg, C. N. [1 ,2 ]
Scher, H. I. [3 ]
Molina, A. [4 ]
North, S. [5 ]
Mainwaring, P. [6 ,7 ]
Hao, Y. [8 ]
Gagnon, D. [9 ]
Kheoh, T. [4 ]
Haqq, C. M. [4 ]
de Bono, J. [10 ,11 ]
机构：
[1] San Camillo Hosp, Dept Med Oncol, Rome, Italy
[2] Forlanini Hosp, Dept Med Oncol, Rome, Italy
[3] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA
[4] OrthoBiotech Oncol Res & Dev, Los Angeles, CA USA
[5] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[6] Haematol Clin Australasia, Milton, MA, Australia
[7] Oncol Clin Australasia, Milton, MA, Australia
[8] Johnson & Johnson Pharmaceut Serv, Global Strateg Mkt & Market Access, Raritan, NJ USA
[9] Thomson Reuters, Strateg Consulting Healthcare, Santa Barbara, CA USA
[10] Inst Canc Res, Sutton, Surrey, England
[11] Royal Marsden Hosp, Med Sect, Sutton, Surrey, England
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71966-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S488 / S489
页数：2
相关论文
共 50 条
  • [31] Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
    Wilson, Brooke E.
    Armstrong, Andrew J.
    de Bono, Johann
    Sternberg, Cora N.
    Ryan, Charles J.
    Scher, Howard, I
    Smith, Matthew R.
    Rathkopf, Dana
    Logothetis, Christopher J.
    Chi, Kim N.
    Jones, Robert J.
    Saad, Fred
    De Porre, Peter
    Tran, NamPhuong
    Hu, Peter
    Gillessen, Silke
    Carles, Joan
    Fizazi, Karim
    Joshua, Anthony M.
    EUROPEAN JOURNAL OF CANCER, 2022, 170 : 296 - 304
  • [32] Abiraterone Acetate (AA) in pre- and post-docetaxel (DX) metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular (CV) events
    Cavo, A.
    Rubagotti, A.
    Zanardi, E.
    Fabbroni, C.
    Zinoli, L.
    Arboscello, E.
    Bellodi, A.
    Spallarossa, P.
    Boccardo, F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 77 - 77
  • [33] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.
    de Velasco, Guillermo
    Lora, David
    Lorente, David
    Choueiri, Toni K.
    Sweeney, Christopher
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [36] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Ryan, Charles J.
    Smith, Matthew Raymond
    De Bono, Johann Sebastian
    Molina, Arturo
    Logothetis, Christopher
    De Souza, Paul L.
    Fizazi, Karim
    Mainwaring, Paul N.
    Piulats Rodriguez, Jose Maria
    Ng, Siobhan
    Carles, Joan
    Mulders, Peter
    San Kheoh, Thian
    Griffin, Thomas W.
    Small, Eric Jay
    Scher, Howard I.
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301
    Montgomery, Bruce
    Kheoh, Thian
    Molina, Arturo
    Li, Jinhui
    Bellmunt, Joaquim
    Tran, NamPhuong
    Loriot, Yohann
    Efstathiou, Eleni
    Ryan, Charles J.
    Scher, Howard I.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2015, 67 (05) : 866 - 873
  • [39] Improved survival in elderly (≥75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study
    Mulders, P. F. A.
    Molina, A.
    Marberger, M.
    Saad, F.
    Li, J. H.
    Kheoh, T.
    Haqq, C. M.
    Fizazi, K.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E127 - U517
  • [40] Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study
    Omrcen, Tomislav
    Eterovic, Davor
    Vrdoljak, Eduard
    ANTI-CANCER DRUGS, 2020, 31 (07) : 742 - 746
12345